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Abstract. Amyloid deposition occurs in aging, even in individuals free from cognitive symptoms, and is often interpreted as
preclinical Alzheimer’s disease (AD) pathophysiology. YKL-40 is a marker of neuroinflammation, being increased in AD,
and hypothesized to interact with amyloid- (A) in causing cognitive decline early in the cascade of AD pathophysiology.
Whether and how A and YKL-40 affect brain and cognitive changes in cognitively healthy older adults is still unknown.
We studied 89 participants (mean age: 73.1 years) with cerebrospinal fluid samples at baseline, and both MRI and cognitive
assessments from two time-points separated by two years. We tested how baseline levels of A42 and YKL-40 correlated
with changes in cortical thickness and cognition. Thickness change correlated with A42 only in A42+ participants (<600
pg/mL, n = 27) in the left motor and premotor cortices. A42 was unrelated to cognitive change. Increased YKL-40 was
associated with less preservation of scores on the animal naming test in the total sample (r = –0.28, p = 0.012) and less
preservation of a score reflecting global cognitive function for A42+ participants (r = –0.58, p = 0.004). Our results suggest
a role for inflammation in brain atrophy and cognitive changes in cognitively normal older adults, which partly depended on
A accumulation.
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INTRODUCTION
Low level of cerebrospinal fluid (CSF) amyloid-
 42 (A42) represents a major risk factor for
Alzheimer’s disease (AD) [1] but it is also a com-
monly described feature within clinically normal
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aging populations [2]. Numerous studies show high
concordance between low CSF A42 and high ligand
retention on amyloid positron emission tomography
(PET), irrespective of clinical status [3] indicat-
ing that low CSF A42 reflects amyloid deposition.
However, we still do not understand why A42
is related to the development of disease in some
persons, while others seem able to cope with sub-
stantial amyloid burden. Therefore, many studies
point to an inconsistent relationship between A42,
brain atrophy as measured with magnetic reso-
nance imaging (MRI), and cognition in aging, which
can be caused by other factors that interact with
amyloid [4].
In the sense of these interactions with amy-
loid, neuroinflammation has been proposed as one
critical factor. Similar to amyloid deposition, neu-
roinflammation occurs in both AD and normal aging
[5, 6]. Although neuroinflammation is observed in
pathologically vulnerable brain regions in AD, it
remains unclear whether insoluble A deposits or
neurofibrillary tangles are causing inflammation [7]
or whether inflammation may actually promote or
accelerate deposition of A [8]. In addition, by
means of neuropathological studies, we know that
increasing age is associated with increased microglial
activation accompanied by production of inflamma-
tory cytokines and compromised neuronal function,
including synaptic dysfunction [9]. The chitinase-3-
like protein 1 (YKL-40) is a CSF biomarker reflecting
neuroinflammation [10]. Some studies have reported
higher YKL-40 levels in AD [11], and these increases
have also been associated with conversion to demen-
tia [10, 12, 13]. YKL-40 has also been related to
brain atrophy in AD [14, 15]. However, the capa-
bilities of YKL-40 to distinguish AD from controls
have so far been found to be moderate in compari-
son with other CSF-markers such as total tau (T-tau),
phosphorylated tau (P-tau), and A42 [16], and some
report no relationship with AD [17, 18]. This may
suggest that YKL-40 levels correlate with brain and
cognitive processes just as much in normal aging as
in AD.
In the present study, we tested the role of neuroin-
flammation in cortical atrophy and cognitive change
in older adults without cognitive symptoms with
either abnormal or normal amyloid status. For this
purpose, we used baseline measures of A42 and
YKL-40, a measure of the brain cortical thickness
and the scores of cognitive tests. Although there
are reasons to expect a relationship between amy-
loid levels and neuroinflammation, no previous study
has directly tested how these biomarkers interact
in contributing to brain and cognitive decline in
aging. While the role of YKL-40 in normal aging
is almost unexplored, previous research on amyloid-
related changes in the aging brain are conflicting,
with some reporting more atrophy [19–21] in sub-
jects with lower CSF A42 levels and others larger
volumes [22], or non-linear relationships [23]. It has
also been suggested that the correlations between
A42 and atrophy can be different for A42 positive
versus negative individuals. This has been described
in the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database [24, 25], but has to our knowledge
not been tested in other samples. With regard to cog-
nitive changes, studies indicate that amyloid levels
correlate, albeit not strongly, with cognitive func-
tion in normal populations [26]. Because of these
controversies, it is necessary to study other fac-
tors that may show either amyloid-independent or
amyloid-dependent relationships to atrophy and cog-
nitive changes.
MATERIALS AND METHODS
Participants
The sample consisted of cognitively healthy older
adults undergoing elective spinal surgery under spinal
anesthesia and turning 65 years or older the year
of inclusion. Exclusion criteria were dementia, pre-
vious stroke with sequelae, Parkinson’s disease, or
other neurological condition likely to affect cogni-
tion. From the full sample recruited (n = 172), we
selected those having available baseline CSF mea-
sures and both MRI and cognitive evaluation at the
two time points (mean time between MRI scans: 2.18
years). None developed mild cognitive impairment at
follow up. A total of 89 participants were included
in the current analyses. Demographics, including
years of education, are summarized in Table 1. The
cognitive evaluation was identical at the two time
points and included the Word List Memory Task
from the Consortium to Establish a Registry for
Alzheimer’s Disease battery (CERAD) [27], which
was based on recall, the Animal Naming Test (ANT)
[28] and the Trail Making Test B (TMTB) [29].
These tests represent verbal memory, verbal flu-
ency, and executive function. We also report here
the results of the Mini-Mental Status Examination
(MMSE) [30]. In addition, the Clock Drawing Test
[31] and Kendrick Object Learning Test [32] were
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Table 1
Demographics, cognitive, and CSF data of the participants included in the analyses
Full sample A– group A+ group
N = 89 N = 62 N = 27
Mean (SD) Mean (SD) Mean (SD)
Range Range Range
Sample & Demographics
Age (years) 73.1 (6.01) 73.2 (6.3) 72.91 (5.38)
64.74–89.79 64.74–89.79 64.95–82.52
Sex (men/women) 46/43 29/33 17/10
Time between (years) 2.17 (0.28) 2.18 (0.26) 2.17 (0.33)
1.55–2.88 1.55–2.87 1.71–2.88
MMSE baseline 29.13 (1.27) 29.09 (1.40) 29.22 (0.93)
25–30 25–30 27–30
MMSE 2 years 29.05 (1.21) 29.14 (1.19) 28.85 (1.23)
24–30 24–30 26–30
Education (years) 14.49 (3.34) 14.82 (3.31) 13.72 (3.35)
8–23 8–23 8–19
WMH baseline (mm3) 6224.45 (7161.05) 6553.5 (7881) 4946.4 (4486.1)
1143.4–36056.6 1143.40–36056.6 1338.2–22018.5
WMH 2 years (mm3) 7091.84 (8343.7) 7670.9 (9365.2) 5777.7 (5277.05)
1098.9–40698.6 1098.9–40698.6 1611.7–24642.6
WMH change (mm3) 0.105 (0.098) 0.103 (0.100) 0.108 (0.093)
–0.28–0.45 –0.28–0.45 –0.09–0.26
Cognition
TMTB - baseline+ 118.55 (60.28) 112.61 (44.33) 132.69 (64.13)
34–466 34–246 64–466
TMTB 2 years+ 116.23 (56.57) 106.64 (50.53) 137.89 (64.13)
31–306 31–267 72–306
CERAD baseline 6.78 (1.76) 6.73 (1.67) 6.89 (2)
3–10 4–10 3–10
CERAD 2 years 7.69 (1.72) 7.61 (1.55) 7.85 (2.1)
3–10 5–10 3–10
ANT baseline 20.67 (5.45) 20.69 (5.22) 20.63 (6.04)
5–32 10–32 5–30
ANT 2 years 23.27 (6.09) 23.85 (5.9) 21.93 (6.4)
7–38 7–38 10–38
CSF biomarkers
CSF - A42 (pg/ml) 721.22 (204.65) 831.25 (131.07) 467.19 (72.45)
275–1175 605–1175 275–587
CSF – T-Tau (pg/ml) 373.4 (142.05) 361.28 (123.27) 401.23 (177.45)
114.7–785.9 181.8–767.9 114.7–785.95
CSF – P-tau (pg/ml) 60.42 (18.37) 59.76 (17.1) 61.93 (21.34)
26–110 32–110 26–103
YKL - 40 (ng/ml)∗ 220.02 (73.9)∗103 219.80 (73.39)∗103 220.521 (76.47)∗103
92.11–441.5∗103 97.19–441.5∗103 92.11–348.3∗103
MMSE, Mini-Mental State Examination; WMH, white matter hypointensities; TMTB, Trail Making Test – B; ANT, Animal Naming test;
CERAD, Word list memory task from the consortium to establish a registry for Alzheimer’s disease battery. +Missing data of n = 1 subject;
∗excluded 1 subject below detection limit.
administered, but were not included here because they
tend to be less sensitive to variation in cognitively
healthy samples.
Ethical considerations
The study was conducted in accordance with the
Declaration of Helsinki and approved by the Regional
Committee for Ethics in Medical Research in Norway
(REK 2011/2052). All participants provided written
informed consent.
Rates of change and cognition factor
We computed the annual rate of change in the
scores obtained from the cognitive tests using the
symmetrized annual percent change. These values
were obtained as the difference in scores between
time points divided by its mean and by the time
between them. The obtained scores are referred to as:
CERAD-change, ANT-change, and TMTB-change.
We also calculated a global cognition change fac-
tor using principal component analysis on the rates
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of change obtained from the three tests. We used
the first component, explaining the largest amount of
variance. We refer to this score as COGfac-change.
CSF measures
CSF samples were taken at the time of the induc-
tion of spinal anesthesia. CSF was collected in
polypropylene tubes, centrifuged, the supernatant
aliquoted in polypropylene vials, frozen as soon as
possible, and stored at –80◦C pending analyses. CSF
levels of A42, T-tau, and P-tau were determined
using INNOTEST enzyme-linked immunosorbent
assays (Fujirebio, Ghent, Belgium). YKL-40 con-
centrations were measured using a commercially
available ELISA (R&D systems, Minneapolis, MN).
All analyses were performed by board-certified labo-
ratory technicians, who were masked to clinical data,
using one batch of reagents with intra-assay coeffi-
cients of variation below 10%.
Magnetic resonance imaging
In each scanning session, a T1-weighted MPRAGE
3D image was acquired in a 1.5T Siemens Avanto
scanner using a 12-channel head coil (TR = 2400 ms,
TE = 3.79 ms, slice thickness = 1.20 mm, pixel spac-
ing = 1.25 × 1.25 mm).
MRI processing
Structural MPRAGE scans were processed with
FreeSurfer (version 5.3) and its longitudinal stream
(https://surfer.nmr.mgh.harvard.edu). The standard
FreeSurfer pipeline performs a set of automated pro-
cedures for the cortical reconstruction and volumetric
segmentation of the individual scans [33, 34]. In addi-
tion, the FreeSurfer longitudinal stream includes a set
of methods designed to minimize the bias to any time
point and which has been shown to lead to increased
statistical power, better separation of groups based
on atrophy and higher reproducibility [35–37]. Using
these tools, we obtained vertex-wise maps of sym-
metrized atrophy rate, defined as the normalized
difference in thickness at each vertex per year.
FreeSurfer reconstructed brain surfaces were visually
inspected and manually corrected when necessary.
Manual interventions included the removal of non-
brain areas and the use of control points to guide the
automated reconstruction of white and pial surfaces.
We obtained the volume of WM hypointensities
(WMH) from the automated freesurfer subcortical
segmentation [34]. WMH appear as dark WM on
the T1-weighted image and the overall WMH vol-
ume is obtained from the sum of regions within the
WM with T1-intensity values within a certain range
defined from the probabilistic atlas. This measure is
related to WM lesions and vascular disease and it has
shown good agreement with manual measurements
[38] as well as good reliability in aging cohorts [39].
In addition, we obtained the hippocampal volumes
from the same processing stream.
Statistics
In order to test the overall effects of time on
cortical thickness, the surface-based data represent-
ing thickness change for each subject was fit into
a GLM model for group-statistics. We first calcu-
lated the mean rate of change between acquisitions
for the whole sample, using a one-sample t-test
model. We then performed vertex-wise correlations
and tested interactions to investigate relationships
between thickness, CSF markers, and cognition.
First, participants were divided into two subgroups
according to their levels of CSF A42, namely A+
(<600 pg/mL) and A– (≥600 pg/mL). Because sev-
eral cutoff values of CSF A42 levels are described
in the literature, ranging from 500 to 650 pg/mL [19,
40–42], we used a rather conservative level of 600
pg/mL, which is in-between the cut-off used in clini-
cal routine in the Clinical Neurochemistry Laboratory
and that for amyloid PET positivity [43], and also to
accommodate possible variation or bias in the mea-
surements and to ensure a considerable number of
subjects within the group of healthy older adults with
amyloid positivity.
General linear models (GLM) were used for
vertex-wise analyses of cortical thickness change.
All statistical maps were corrected for family wise-
error (FWE) using precomputed simulated data in
FreeSurfer [44]. Significance threshold was set at
a p-value of 0.05, both for the initial thresholding
of the maps and for the identification of significant
clusters. Age and gender were used as covariates
in all the surface-based analyses. We first calcu-
lated the mean rate of change between acquisitions
as symmetrized annual percent change, and then
tested whether this was different from zero. Addi-
tional GLMs were used to compare rate of change
between the amyloid groups, and to test the rela-
tionship between thickness change and each variable
of interest, i.e., the two CSF biomarkers and longi-
tudinal change in each cognitive test score. To test
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interactions, we used a model with two groups (i.e.,
subjects being positive or negative for A42) and CSF
YKL-40 levels or the cognitive score as the contin-
uous variable, and tested whether the slopes of the
groups differed.
We tested for group differences in 2-year change
in the cognitive scores by use of t-tests. We also used
t-test to test for group differences in education and
WMH, and used partial correlations, controlling for
age and gender, to test whether these variables were
related to CSF levels of YKL-40, cognitive scores,
or mean cortical thickness. Statistics on non-imaging
data were performed with SPSS and MATLAB
tools.
RESULTS
Demographics and cognitive data
A total of 27 subjects were included in the A+
group and 62 in the A– group. Principal component
analysis of cognition change depicted three com-
ponents, from which the first one, used as global
cognition change factor (COGfac-change) accounted
for 42.63% of the total variance. There were no
group differences in the rates of change in any of
the cognitive measures or in baseline CSF YKL-
40 and P-Tau or T-tau levels. The results of the
TMTB at the second time point differed between
groups (t = 2.54, p = 0.016). However, the rates of
change within this measure were not significantly
different (t = 1.3, p = 0.16). Years of education did
not differ between groups (t = 1.43, p = 0.155) and
did not correlate with CSF levels, cognitive scores
or mean thickness values (p > 0.05 in all tests). In
addition, there were no differences between groups
in WMH at either time point or in percent change
(Table 1), and WMH did not correlate with CSF YKL-
40 levels or any of the cognitive measures used (all
p’s>0.05).
Mean longitudinal changes in cortical thickness
We observed an average rate of cortical thinning of
0.53% (SD: 1.0%) per year in the full sample. Gen-
eral thinning was observable across large regions of
the cortex (Fig. 1). Reductions in cortical thickness
were significant (FWE corrected level of p < 0.05) in
several clusters located bilaterally in superior pari-
etal, supramarginal, precuneus, isthmus cingulate
posterior cingulate, postcentral and paracentral cor-
tices, in the right hemisphere including the superior
frontal, caudalmiddlefrontal, inferior parietal, pre-
central fusiform, and parahippocampal cortices, as
well as in left lingual cortex.
Aβ42 and cortical thinning
Overall change in cortical thickness did not dif-
fer between A+ and A– participants (–0.50% and
–0.54%, respectively, t = 0.11, p = 0.91). We used
a vertex-wise GLM on the surface to investigate
Fig. 1. A) Mean effects of time on cortical thickness within the full sample. Percentage of thickness change measured between baseline
and the 2-years scan. Green-blue areas indicate decreases over time and yellow-red indicate increases (see legend). B) Significant clusters
showing the effect of time on cortical thickness after correction for multiple comparisons (p < 0.05).
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Fig. 2. A) Region with a group-interaction with A42 levels and cortical thickness change. B) Scatter plots showing the relationship between
thickness change and A42 levels for the two groups separately.
the effect of CSF A42 levels on regional thick-
ness change. Using a between-group comparison, we
found that regional change in thickness did not differ
between groups. We then created a design with
separate slopes for the relationship between A
and thickness change for the A+ versus the A–
groups. We found a cluster where this interaction
was significant, covering part of the left precen-
tral, left caudal middle frontal and superior frontal
cortex (p < 0.05, FWE corrected). In this region,
there was a negative relationship between CSF
A42 levels and the reduction of cortical thick-
ness in the A+ group, but not in the A– group
(Fig. 2).
Aβ42 and cognition
Using partial correlations and A42 as a con-
tinuous variable, we did not find any relationship
between CSF levels of A42 and the global cog-
nitive change or change in any of the specific
cognitive measures. More specifically, the correlation
with TMTB-change, a test that showed differences
between groups at the second time point, was not
significant either (r = –0.173, p = 0.115).
YKL-40, Aβ42 , and brain measures
We did not find any relationship between YKL-
40 levels and change in cortical thickness or CSF
A42 levels. In addition, there were no interactions
between these three measures. Even if it was not the
aim of the current study, we observed that YKL-40
and hippocampal atrophy correlated on a trend level
only (A+ p = 0.06/ A– p = 0.09). Therefore, more
thorough analyses will be the focus of future studies.
YKL-40 and cognition
Change in the animal naming test (ANT-change)
correlated with CSF YKL-40 levels within the whole
sample, in that higher YKL-40 levels were related to
more decline in the test scores (r = –0.28, p = 0.012)
(Fig. 3A). Note that we observed rates of change
above zero due to practice effects [45]. No signif-
icant correlations between YKL-40 and the other
cognitive measures were found, but a trend was
observed between YKL-40 and global cognition
change (COGfac-change, r = –0.185, p = 0.096).
Finally, we explored correlations with the
CSF YKL-40 levels and cognition in A+ and
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Fig. 3. CSF YKL-40 levels and cognition. A) YKL-40 and changes in animal naming test in the full sample. B) Correlation between YKL-40
and global cognition in A+ and A– groups of participants.
A– participants. In the A+ group, we found
a correlation between levels of YKL-40 and the
COGfac-change (r = –0.58, p = 0.004, see Fig. 3B).
This correlation was not found in the A– group
(r = –0.008, p = 0.955). These correlations were sig-
nificantly different, as evidenced by use of the
Fisher r-to-z transformation (z = 2.72, p = 0.0065,
two-tailed).
Cortical thickness and cognition
Longitudinal change in cortical thickness corre-
lated positively with change in the results of the
animal naming test (p < 0.05), meaning that more
thinning was associated with more decline in test
scores. We found two significant clusters located in
the right hemisphere, covering parts of the supra-
marginal, postcentral, and inferior parietal cortices
(Fig. 4).
Exploring possible single-subject effects
We excluded a single subject having MMSE of 24
at the second timepoint, which was classified into the
A– group and we observed that the main results
of the study were preserved. Specifically, the corre-
lations between CSF YKL-40 levels and the ANT
scores (r = –0.281, p = 0.011), and with the COGfac-
change in the A– group (r = 0.103, p = 0.446) were
preserved. In addition, the vertex-wise comparisons
performed with Freesurfer yielded similar results.
DISCUSSION
In the present study, we showed that neuroinflam-
mation, as indexed by CSF levels of YKL-40, were
associated with reduced cognitive function two years
Fig. 4. Correlation between change in cortical thickness and
change in the results of the animal naming test. Red-yellow areas
indicate that changes in thickness and changes in cognition have the
same direction. Only results within significant clusters are shown.
later in cognitively normal older adults who were
positive for A42. Intriguingly, no relationship was
observed for A negative participants. As CSF levels
of A42 and YKL-40 were not related, this could indi-
cate that these biomarkers are indicators of distinct
processes in the brain that have additive detrimental
effects on cognitive function in older adults at risk for
AD. In addition, we found that CSF A42 levels cor-
related with cortical atrophy only in amyloid positive
participants. Seen together, these results indicate that
mechanisms for brain atrophy and cognitive decline
might be different in older adults that are positive in
comparison with those negative for amyloid, under-
scoring the need to understand how amyloid relates
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to brain atrophy in cognitively normal older adults.
The implications of the results are discussed below.
Age-related cortical thinning
We observed a pattern of age-related cortical
thinning from baseline to the 2-year follow-up acqui-
sition. This pattern is in accordance with what has
been reported in other studies of healthy older adults
and justifies the suitability of our sample to study
the effect of CSF markers in this population. Higher
rates of thinning were observed in areas correspond-
ing to the default mode network, a system that is
functionally altered in aging [46]. Interestingly, the
higher vulnerability to cortical atrophy in areas of
the DMN healthy aging has been already discussed
elsewhere [47].
Neuroinflammation and cognition in Aβ+ older
adults
Here we used CSF YKL-40 levels as a measure
of neuroinflammation and we found that increased
levels of this biomarker were correlated with global
changes in cognition in the A+ group, indicating
that neuroinflammation might play an important role
for cognitive changes in older adults with altered
amyloid status. In addition, increasing age has been
associated with increased microglial activation [9]
increased levels of CSF YKL-40 are observed in AD
patients [10, 13, 16] but this is not invariably found
[17, 18]. However, no studies have previously tested
whether this biomarker is increased also in healthy
older adults with altered amyloid levels. Intriguingly,
our result suggests that even if the level of neuroin-
flammation as indexed by YKL-40 does not vary as
a function of amyloid accumulation, the ability of
the brain to cope with the inflammation is differ-
ent depending on the subject amyloid status. Thus,
inflammation is associated with cognitive reduction
over time in the presence of higher amyloid levels
only, with the lower risk older adults probably being
able to better cope with the burden of neuroinflam-
mation. This is not an on-off mechanism, however,
as we found that changes in the animal naming test
correlated with YKL-40 levels also within the full
sample. Thus, the present results indicate that YKL-
40 indexes neuroinflammatory processes that have
mild but nevertheless detrimental effects on cognitive
function in older adults, and that these detrimental
effects are significantly larger in participants with
increased A42 levels.
Cortical thinning at the different CSF Aβ42 levels
In addition to the A-dependent effects of neuroin-
flammation on cognition, we found that decreased
CSF A42 correlated with cortical thinning in the
A+ participants. This further indicate that there
might be degenerative processes occurring at this nar-
row range of A42 levels even in individuals free from
clinical symptoms. This pattern has previously been
described within the ADNI cohort of normal older
adults [24, 25]. These two studies found that only
under a certain threshold of A42 levels in CSF, A42
correlated with accelerated brain atrophy. The present
study demonstrates this pattern in a different sample
than the ADNI database. Taken together, these find-
ings indicate that amyloid positive older adults are
less able to cope with processes in the brain that might
otherwise not be as harmful in older adults without
evidence of brain amyloid accumulation. Previous
studies have reported that the anatomical localization
of A-atrophy relationships tends to vary and seems
to be rather widely distributed (for a review, see [47]).
This fits well with the fact that amyloid accumula-
tion in the cortex [48] is less anatomically specific
than for instance neurofibrillary tangles, which ini-
tially is restricted to the medial temporal cortex. In
the present study, the stronger relationship between
A42 and cortical thinning in the A42+ group com-
pared with the A42- groups was seen in the motor
and premotor cortices, overlapping reported effects
from previous studies [21]. However, given the gen-
erally widespread distribution of effects in previous
studies, we advise against putting too much weight
on the precise anatomical location of this effect.
Neuroinflammation, amyloid, and changes in
cognition
Previous literature has described null or rela-
tively weak relationships between common CSF AD
biomarkers such as A42 and memory/cognition in
healthy elderly participants [26, 47, 49]. This has
encouraged the community to study the roles of alter-
native markers in addition to amyloid to better explain
cognitive reductions and brain atrophy in aging. Our
results, though being moderate in strength, indicate
that YKL-40 is one such marker, primarily when
seen in coexistence with altered levels of established
risk markers such as A42. This fits with theories of
amyloid and neuroinflammation working together to
cause cognitive decline and brain atrophy in older
adults with neurodegenerative conditions such as
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AD [6], even if the evidence for these theories in
humans is scarce and to a large extent based on
genetic studies. Further, additive roles of amyloid
accumulation and neuroinflammation have not been
tested in cognitively normal older adults. The results
of the present study suggest that effects of inflam-
mation on cognitive decline in older adults without
dementia may partly depend on amyloid status.
Adding to this, we found that decline in the same
cognitive test also correlated with longitudinal cor-
tical atrophy. Participants with less capability to
maintain or improve performance on the animal nam-
ing test showed more decreases in cortical thickness.
These results are in accordance with previous studies
showing correlations between longitudinal changes
in brain structure and changes in cognition [50–52].
Although being related with reductions in cog-
nition, CSF YKL-40 levels did not correlate with
cortical thinning. Some previous studies have
reported correlations between thinner cortex and
higher YKL-40 levels [14, 15] or other markers of
inflammation [5], while others did not find rela-
tionships with measures of brain structures such as
hippocampal volume [53]. The studies mentioned
above were all cross-sectional, in contrast to the
present longitudinal design. Further, these former
studies included patients with mild cognitive impair-
ment or AD, thus not being fully comparable. Still,
when the present results are seen in contrast to
the identified relationship between amyloid levels
and cortical thinning in the amyloid positive par-
ticipants, it is evident that the relationship between
amyloid levels, neuroinflammation, and brain atro-
phy is complex. To get a deeper understanding of
the mechanisms at play, we will likely also need
to include additional biomarkers as well as genetic
factors in the analyses.
We performed several tests to evaluate the effect
of possible factors confounding our results. We first
confirmed that excluding one subject with MMSE
of 24 at follow-up did not change the findings, and
we found that variables such as WMH or years of
education were not correlated with CSF markers or
cognition.
However, other neuropathological processes than
A could be associated with inflammation even
in cognitively well-functioning older adults, which
should be focus of future studies. Similarly, even if
we did not find any relationship between WMH and
the CSF measures or cognitive scores, we believe that
more accurate measures of white matter lesions can
be used to evaluate in a deeper way the effect of
cerebrovascular alterations related to CSF markers
in aging. Finally, it has been reported that education,
and more generally, cognitive reserve, has an impor-
tant impact on the aging brain, and that it may interact
with cortical thickness, CSF biomarkers, and cogni-
tion [54]. However, in our study, years of education
were not correlated with cognition or CSF scores.
Our study has several limitations. We report signif-
icant correlations at the uncorrected level of p < 0.05
and therefore our results need to be considered
exploratory. However, taking in account the novelty
of the subject and the reduced number of related
studies, we believe that our findings add relevant
information to the field. In addition, as mentioned,
further studies should include a wider range of
biomarkers, as well as other variables, including
genetic and environmental factors and a higher num-
ber of data-points. In this sense, we tested whether
years of education had an impact on our results
and we did not find significant correlation. How-
ever, we believe that further studies are needed to
investigate these factors in more detail. Similarly,
hippocampal atrophy was related to YKL-40 on a
trend level, and these results will be followed up in
future studies with more in-depth analyses. Another
limitation refers to the characteristics of our sam-
ple (participants undergoing spinal surgery), which
may be not fully representative of a normal aging
population. However, the cognitive scores did not
indicate cognitive decline, and the rate of change in
cortical thickness, as well as the anatomical pattern
of cortical thinning, was comparable to those com-
monly observed in other samples of healthy aging
[50]. We believe this supports the validity of the
findings.
To conclude, one important theory holds that
sustained inflammatory responses to amyloid accu-
mulation increase brain atrophy in AD [6, 55], and the
increased levels of neuroinflammation observed also
in cognitively normal older adults make it important
to investigate amyloid—inflammation relationships
also in non-demented. Here we found that YKL-40,
as a measure of neuroinflammation, correlated with
global cognitive decline especially in amyloid pos-
itive older adults. In contrast, CSF A42 levels per
se did not correlate with cognitive decline, but still
were related to brain atrophy in amyloid positive par-
ticipants. Put together, these findings highlight the
need for considering how newer biomarkers interact
with the established ones in the study of cognitive
and brain changes in aging. This may provide bet-
ter understanding of the processes that are crucial
838 R. Sala-Llonch et al. / CSF Inflammation and Amyloid Markers in Aging
in the transitional phase between normal aging and
neurodegeneration.
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